期刊文献+

哌拉西林-他唑巴坦治疗产超广谱β-内酰胺酶肠杆菌科细菌血流感染的疗效观察 被引量:1

Observation on the efficacy of piperacillin and tazobactam in the treatment of blood stream infection of enterobacteriaceae producing extended spectrum beta-lactamases
下载PDF
导出
摘要 目的探讨对产超广谱β-内酰胺酶(ESBLs)肠杆菌科细菌所致血流感染的患者,应用哌拉西林-他唑巴坦治疗的效果。方法选取80例因ESBLs细菌感染所致血流感染患者作为研究对象,按照随机数字表法分成两组,即试验组与对照组,每组40例,对照组采取美罗培南的用药治疗方式,试验组采取哌拉西林-他唑巴坦治疗方式,在经14 d的治疗后对两组治疗效果、血清炎性指标变化进行评价。结果临床疗效表明,试验组中38例治疗有效,总有效率为95.00%,对照组37例治疗有效,总有效率为92.50%,试验组与对照组无显著差异(P>0.05);经治疗后两组血清IL-6、PCT及CRP指标水平均明显较治疗前降低,但是试验组降低幅度明显要比对照组更显著(P<0.05)。结论对于产ESBLs引起的血流感染患者,采取哌拉西林-他唑巴坦治疗的效果满意。 Objective to investigate the efficacy of piperacillin and tazobactam in the treatment of blood stream infection of enterobacteriaceae producing extended spectrum beta-lactamases(ESBLs).Methods 80 cases with ESBLs bloodstream infections caused by bacteria infection patients were divided into two groups according to random number table method,the experimental group and control group,40 cases in each.The control group were given meropenem for treatment,the experimental group were piperacillin and tazobactam.After14 d treatment of two groups,the treatment effect,serum inflammatory indicators were going to be evaluated.Results The clinical effect showed that 38 cases in the experimental group were effectively treated with the total effective rate of 95.00%,while 37 cases in the control group were effectively treated with the total effective rate of 92.50%.There was no significant difference between the experimental group and the control group on the total effective rate(P>0.05).After treatment,serum IL-6,PCT and CRP levels in the two groups were significantly lower than before treatment,but the reduction in the experimental group was more significant than that in the control group(P<0.05).Conclusion The piperacillin-tazobactam is a satisfactory treatment for esbls-induced bloodstream infection,which is worthy of promotion.
作者 李嘉莹 何赛珠 林凤萍 LI Jia-ying;HE Sai-zhu;LIN Feng-ping(Department of Pharmacy,Tongjiang Pharmaceutical Hospital,Foshan 528300,China)
出处 《中国处方药》 2020年第5期88-89,共2页 Journal of China Prescription Drug
基金 广东省医学科研基金项目(201807006)。
关键词 哌拉西林-他唑巴坦 产超广谱Β-内酰胺酶 血流感染 疗效 炎性因子 Piperacillin-tazobactam Producing extended spectrum beta-lactamases Bloodstream infection Curative effect Inflammatory cytokines
  • 相关文献

参考文献8

二级参考文献32

共引文献51

同被引文献16

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部